EVOLUTION OF D-DIMER AS A MARKER OF BLEEDING RISK ON ECMO
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Strasbourg, France
About this trial
ECMO (extracorporeal membrane oxygenation) is a life-saving device, used in intensive care to treat severe respiratory or cardiac failure. However, it carries a high risk of serious life-threatening bleeding.
Bleeding complications have been attributed to coagulopathy triggered either by the underlying pathology or by the extracorporeal circuit itself, as well as excessive or inappropriate anticoagulation initiated to prevent thrombotic complications.
The objective of this cohort is to confirm the interest of the evolution of D-dimers as a prognostic marker of serious bleeding events in patients on veno-venous (VV) or veno-arterial (VA) ECMO, and to determine the threshold.
Eligibility criteria
Qualifiers
Male or female ≥ 18 years of age
Hospitalized patient in intensive care
Implementation of a VV or VA ECMO for less than 24 hours
Patient affiliated to a social protection health insurance scheme
Disqualifiers
Patient on veno-arterial ECMO after cardiac, cardiopulmonary surgery or after placement of a left or biventricular cardiac assist device
Congenital hemostasis disorder or anatomical abnormality predisposing to bleeding
Dying patient on the day of inclusion
Patient under judicial protection
Trial design
Treatments tested in this trial
- Blood sampling collection
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov